Cencora Posts $2.71 Q4 EPS as Drug Distributor Closes Fiscal Year
COR sits 40% above its 52-week low of $244.82.
Summary
Cencora reported fourth-quarter EPS of $2.71, with adjusted EPS of $4.66 versus an IBES estimate of USD 4.58, on revenue of $88.35B and net income of $519.4M. The company guided FY27 adjusted EPS to $19.40-$19.75 and set FY27 revenue growth of 3%-5%, and raised its quarterly dividend to 66c from 60c, a 10% increase. It also introduced new reportable segments — Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other — effective fiscal 2027. Context matters here: the company raised FY26 EPS guidance twice this year, in May and again in August, and pulled forward a $1 billion buyback, so expectations into this print were elevated. The bigger overhang is the Walgreens volume that began moving outside the prime vendor agreement on July 1, disclosed in an August 8-K — this is the first quarterly report to fully reflect that headwind.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Cencora introduced new reportable segments (Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, Other) effective fiscal 2027 and set FY27 revenue growth of 3%-5%.
At the time of this announcement, COR was trading at $343.67 on NYSE in the Trade & Services sector, with a market capitalization of approximately $65B. The 52-week trading range was $244.82 to $377.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.